Natco Pharma signs agreement for manufacture and sale of hepatitis C drug

Natco Pharma has signed a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Daclatasvir, used for the treatment of chronic hepatitis C.Natco Pharma, in a BSE filing today said: “It has signed a non-exclusive, royalty free licensing agreement with the Medicines Patent Pool (MPP) and Bristol-Myers Squibb to manufacture and sell generic versions of Bristol—Myers Squibb’s

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

GENEVA, January 20, 2016 /PRNewswire/ --Four companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries The Medicines Patent Pool (MPP) announced its first round of sub-licences for the generic production of Bristol-Myers Squibb's daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus. Generic companies Cipla, Emcure, Hetero and Natco have signed n